We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » ICER Finds Acute Treatments for Migraine Might Be Too Costly
ICER Finds Acute Treatments for Migraine Might Be Too Costly
Three acute treatments for migraine — Eli Lilly’s Reyvow (lasmiditan), Biohaven’s rimegepant, and Allergan’s Ubrelvy (ubrogepant) — may not be cost-effective, according to the Institute for Clinical and Economic Review (ICER).